Elizabeta C. Popa, M.D.

Medical Oncology


·       Elizabeta C Popa, Manish A Shah  Met, IGF1R, and Other New Targets in Upper GI Malignancies." Current treatment options in oncology 14.3 (2013): 321-336

·       Elizabeta C Popa, Manish A Shah  Chapter 3: Role of [18F]-FDG PET/CT Imaging in Gastrointestinal Malignancies  Recent Advances in Surgery:35 Irving Taylor, Colin D Johnson © 2013 JP Medical Ltd

·       Elizabeta Popa,  Felice Schnoll-Sussman, Arun Jesudian, Govind Nandakumar, and Manish H. Shah Uncommon Cancers of the Stomach Textbook of Uncommon Cancer, Fourth Edition. Edited by Derek Raghavan, Charles D. Blanke, David H. Johnson, Paul L. Moots, Gregory H. Reaman, Peter G. Rose and Mikkael A. Sekeres. © 2012 John Wiley & Sons, Inc. Published 2012 by John Wiley & Sons, Inc

·       Josef Maertz, Sarika Jain, Linda T Vahdat, Lihui Qin, Juan M Mosquera, Cristina R Antonescu, and Elizabeta C Popa High-grade KIT- negative sarcoma of the small bowel in a patient with CML on long-term tyrosine kinase inhibitors: case report and review of the literature  Journal of Clinical Oncology JCO/2012/427989

·       Antonio Jimeno, Lori J. Wirth, Marshall R. Posner, Roger B. Cohen, Jared Weiss, Elizabeta C. Popa, Nabil F. Saba, Kenneth F. Grossmann, Ammar Sukari, Ezra E.W. Cohen, Athanassios Argiris, Carolyn H Condon, Dawn Wilson, Ty McClure, Marat Alimzhanov, Scott Pearsall, Kenneth M. Attie, Matthew L. Sherman, Shuchi Sumant Pandya Phase II study of dalantercept, a novel inhibitor of ALK1-mediated angiogenesis, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. ASCO 2013 Annual Meeting- Abstract  #115862

·       Allyson J. Ocean, Tanios S. Bekaii-Saab, Imran Chaudhary, Romae Palmer, Paul J. Christos, Alice Mercado, Erika Ocampo Florendo, Veronica A. Rosales, Joseph T. Ruggiero, Elizabeta C. Popa, Melissa Wilson, Mohammad Haroon Ghalib, Yijuan Hou, Umang Shah, Lakshmi Rajdev, Tarek N. Elrafei, George M. Gill, Matthew C. Coffey, Manish A. Shah, Sanjay Goel A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant KRAS-mutant metastatic colorectal cancer (mCRC). ASCO GI 2013 Abstract #105709

·       Douglas Eric Guggenheim, Allyson J. Ocean, Elizabeta C. Popa, Amanda R Magli, Irene Karpenko, Paul J. Christos, Veronica A. Rosales, Erika Ocampo Florendo, Joseph T. Ruggiero, Manish A. Shah The incidence and impact of poor nutrition in gastrointestinal malignancies. ASCO 2013 Annual Meeting -Abstract #116744

·       Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS Jr, Rafii S, Schwartz JD Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008 Jun 20;26(18):2992-8.

·       Hochster H., Luo W., Popa E.C., Lyman T., Mulcahy M., Beatty P.A., Benson A.B., Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299. J Clin Oncol. 2007 Dec 1;25(34):5397-402

·       Haglof K., Popa E., Hochster H. Recent developments in the clinical activity of topoisomerase-1 inhibitors Update On Cancer Therapeutics I  pp.117-145; Elsevier Ltd.,UK 2006

Back to topBack To Top